INT66005

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.61
First Reported 1996
Last Reported 2010
Negated 10
Speculated 8
Reported most in Body
Documents 47
Total Number 56
Disease Relevance 19.21
Pain Relevance 34.52

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Cnr1) aging (Cnr1) plasma membrane (Cnr1)
signal transducer activity (Cnr1)
Anatomy Link Frequency
brain 6
dentate gyrus 2
neuronal 2
spinal 2
pits 2
Cnr1 (Mus musculus)
Pain Link Frequency Relevance Heat
Cannabinoid 1082 100.00 Very High Very High Very High
agonist 594 100.00 Very High Very High Very High
Endocannabinoid 556 100.00 Very High Very High Very High
Analgesic 393 100.00 Very High Very High Very High
antagonist 268 100.00 Very High Very High Very High
Cannabinoid receptor 165 100.00 Very High Very High Very High
Opioid 127 100.00 Very High Very High Very High
cerebral cortex 15 99.92 Very High Very High Very High
fluoxetine 40 99.72 Very High Very High Very High
Pain 182 99.66 Very High Very High Very High
Disease Link Frequency Relevance Heat
Congenital Anomalies 10 99.92 Very High Very High Very High
Neurodegenerative Disease 402 99.84 Very High Very High Very High
Cognitive Disorder 36 99.84 Very High Very High Very High
Status Epilepticus 111 99.72 Very High Very High Very High
Cancer 14 99.68 Very High Very High Very High
Pain 204 99.66 Very High Very High Very High
Targeted Disruption 140 99.52 Very High Very High Very High
Multiple Sclerosis 35 99.44 Very High Very High Very High
Opiate Addiction 16 99.44 Very High Very High Very High
Epilepsy 163 99.32 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Western blot analysis suggested an up-regulation of CB1R in the dentate gyrus of animals with TLE.
Regulation (regulation) of CB1R in dentate gyrus associated with epilepsy
1) Confidence 0.61 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2871782 Disease Relevance 0.75 Pain Relevance 0.59
This prompted us to investigate the CB1 dependent regulation of neurogenesis using a genetic model and an antagonist.
Spec (investigate) Regulation (regulation) of CB1 associated with antagonist and neurodegenerative disease
2) Confidence 0.61 Published 2010 Journal Cell Commun Signal Section Body Doc Link PMC2898685 Disease Relevance 0.66 Pain Relevance 0.15
This result prompted us to investigate CB1 dependent regulation of neurogenesis utilizing CB1 receptor knock out animals as well as the CB1 receptor antagonist AM251 in Nestin-GFP-reporter mice.
Spec (investigate) Regulation (regulation) of CB1 associated with targeted disruption, antagonist and neurodegenerative disease
3) Confidence 0.61 Published 2010 Journal Cell Commun Signal Section Body Doc Link PMC2898685 Disease Relevance 0.95 Pain Relevance 0.21
Therefore, in situ hybridization (ISH) experiments were performed in the adult murine brain to determine possible changes in CB1 mRNA levels in nNOS-KO, compared with WT mice, and to reveal brain areas where CB1 and nNOS were coexpressed in the same neurons.
Spec (possible) Regulation (changes) of CB1 in neurons
4) Confidence 0.59 Published 2001 Journal Eur. J. Neurosci. Section Abstract Doc Link 11168564 Disease Relevance 0.17 Pain Relevance 0.28
CB1 receptor levels were not altered in any of these brain areas (Gonzalez et al 2002; Balerio et al 2004).
Neg (not) Regulation (altered) of CB1 in brain
5) Confidence 0.58 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2656312 Disease Relevance 0.48 Pain Relevance 0.60
On the contrary, it has been reported that chronic fluoxetine causes an up-regulation of CB1 receptors in the Prefrontal cortex (PFC), [78,79], chronic DMI up-regulates CB1 receptors in the hypothalamus and hippocampus [78,79], tranylcypromine (a MAOI) decreases the levels of anandamide in the PFC, hippocampus and hypothalamus, and increases CB1 receptor binding in PFC and the hippocampus, but not in the hypothalamus [78,79].
Regulation (regulation) of CB1 in PFC associated with hippocampus and fluoxetine
6) Confidence 0.58 Published 2007 Journal Clin Pract Epidemiol Ment Health Section Body Doc Link PMC2169225 Disease Relevance 0.30 Pain Relevance 0.90
The results suggest that tranylcypromine induces hypo-activity of the endocannabinoid system in the hypothalamus, but, similar to fluoxetine and DMI, produces an up-regulation of CB1 receptors in other brain areas.
Regulation (regulation) of CB1 in brain associated with endocannabinoid and fluoxetine
7) Confidence 0.58 Published 2007 Journal Clin Pract Epidemiol Ment Health Section Body Doc Link PMC2169225 Disease Relevance 0.05 Pain Relevance 1.05
These results indicate that CB1 activation is necessary during training but not during testing, and that the decreased predisposition observed in CB1 knockout mice is not likely attributable to developmental abnormalities or altered CB1 signaling during feeding on the devaluation test.
Neg (not) Regulation (altered) of CB1 associated with targeted disruption and congenital anomalies
8) Confidence 0.45 Published 2008 Journal Frontiers in Neuroscience Section Body Doc Link PMC2622741 Disease Relevance 0.42 Pain Relevance 0.19
Interestingly, striatal LTD was found to depend on CB1 receptor activation, the primary molecular target in the brain of endocannabinoids (Gerdeman and Lovinger, 2001; Gerdeman et al., 2002).
Regulation (depend) of CB1 in brain associated with endocannabinoid
9) Confidence 0.45 Published 2008 Journal Frontiers in Neuroscience Section Body Doc Link PMC2622741 Disease Relevance 0.07 Pain Relevance 0.32
Finally, by contrast with the observations in motor structures, the status of CB1 receptors remained unaltered in cognition-related regions, such as the cerebral cortex and the hippocampus, during the different phases of CREAE.
Regulation (unaltered) of CB1 in hippocampus associated with multiple sclerosis, cognitive disorder, hippocampus and cerebral cortex
10) Confidence 0.45 Published 2006 Journal Brain Res. Section Abstract Doc Link 16822488 Disease Relevance 0.58 Pain Relevance 0.20
To further examine the role of CB1 and CB2 receptors in antinociception, we evaluated the efficacy of the non-selective cannabinoid receptor agonist, CP 55,940, in models of acute, inflammatory, and neuropathic pain in control mice, CB1 receptor knockout mice, and CB2 receptor knockout mice.
Spec (examine) Regulation (role) of CB1 associated with targeted disruption, antinociception, inflammation, cannabinoid receptor, neuropathic pain and agonist
11) Confidence 0.45 Published 2009 Journal Neuropharmacology Section Abstract Doc Link 19538975 Disease Relevance 0.68 Pain Relevance 0.83
We also examined the effects of CB1 receptor agonists on Ca2+-independent miniature IPSCs (mIPSC).
Spec (examined) Regulation (effects) of CB1 receptor associated with cannabinoid receptor and agonist
12) Confidence 0.45 Published 2000 Journal Eur. J. Neurosci. Section Abstract Doc Link 10998107 Disease Relevance 0.07 Pain Relevance 0.97
Most cannabinoids induce rapid internalization of their receptors via clathrin-coated pits [7], and long-term treatment leads to a significant down-regulation of CB1 receptors (CB1Rs).
Regulation (regulation) of CB1Rs in pits associated with cannabinoid
13) Confidence 0.45 Published 2009 Journal Mol Pain Section Body Doc Link PMC2657119 Disease Relevance 0.18 Pain Relevance 1.01
Most cannabinoids induce rapid internalization of their receptors via clathrin-coated pits [7], and long-term treatment leads to a significant down-regulation of CB1 receptors (CB1Rs).
Regulation (regulation) of CB1 in pits associated with cannabinoid
14) Confidence 0.45 Published 2009 Journal Mol Pain Section Body Doc Link PMC2657119 Disease Relevance 0.18 Pain Relevance 1.00
The effect of a single icv-injection of ACEA or WIN55,212-2 on surface CB1Rs is certainly brief.
Regulation (effect) of CB1Rs
15) Confidence 0.45 Published 2009 Journal Mol Pain Section Body Doc Link PMC2657119 Disease Relevance 0.17 Pain Relevance 0.93
While these results are mostly in line with previous results on CB1 function in adult neurogenesis (reviewed in [13]), they also go beyond what was known since our data elucidate the time-course of this action and reveal a contribution of CB1 to activity-dependent regulation.
Regulation (regulation) of CB1 associated with neurodegenerative disease
16) Confidence 0.45 Published 2010 Journal Cell Commun Signal Section Body Doc Link PMC2898685 Disease Relevance 0.50 Pain Relevance 0.11
To evaluate CB1 mRNA expression changes by activity, we subjected additional 5 female C57Bl/6 to either experimental condition (RUN, ENR, CTR).
Regulation (changes) of CB1
17) Confidence 0.45 Published 2010 Journal Cell Commun Signal Section Body Doc Link PMC2898685 Disease Relevance 0.14 Pain Relevance 0
In contrast, CB1 receptor agonists were ineffective in changing the amplitude of IPSCs in the rat central nucleus and in the basal nucleus of CB1 knock-out mice.
Regulation (ineffective) of CB1 in basal nucleus associated with targeted disruption and agonist
18) Confidence 0.44 Published 2001 Journal J. Neurosci. Section Abstract Doc Link 11717385 Disease Relevance 0.10 Pain Relevance 0.73
Increase of morphine withdrawal in mice lacking A2a receptors and no changes in CB1/A2a double knockout mice.
Neg (no) Regulation (changes) of CB1 associated with targeted disruption, narcan, withdrawal and morphine
19) Confidence 0.44 Published 2003 Journal Eur. J. Neurosci. Section Title Doc Link 12542668 Disease Relevance 0.60 Pain Relevance 0.86
Finally, there were no major changes in the levels and functional activity of CB1 cannabinoid receptors in any brain region in KOR knockout mice.
Neg (no) Regulation (changes) of CB1 in brain associated with targeted disruption and cannabinoid receptor
20) Confidence 0.44 Published 2003 Journal Eur. J. Neurosci. Section Abstract Doc Link 14622180 Disease Relevance 0.35 Pain Relevance 0.59

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox